Patient and provider perspectives are shared regarding available treatments, as well as how to manage treatment-related adverse events that can effect the quality of life for a patient diagnosed with cholangiocarcinoma.
This page is funded by Taiho Oncology, Inc. The faculty and publisher are solely responsible for this content. Taiho does not recommend or endorse the use of its products other than as described in the approved labeling. The content of this page is not medical advice and does not replace independent medical judgment.
EP. 9: Patient Perspective Regarding FGFRi Adverse Event Profiles
January 31st 2024A patient with cholangiocarcinoma shares her experience while being treated with an FGFR inhibitor, as well as insights on what providers should tell their patients to help them best manage or possibly prevent these adverse events.
EP. 14: Key Takeaways For Treating Patients Diagnosed With Cholangiocarcinoma
February 14th 2024Provider and patient perspectives on why patient education about FGFRi treatment-associated adverse events and how to manage them are is essential in helping patients maintain a good quality of life and stay on treatment.
DK210 (EGFR) Induces Immune Response Without Increased CRS or Regulatory T Cells in Solid Tumors
Siglec-15 Represents Potential Therapeutic Target in NSCLC, Other Solid Tumors
Radiomic Biomarkers Predict Response in Lung and Liver Uveal Melanoma Metastases
BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors
2 Commerce Drive
Cranbury, NJ 08512